Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antiretroviral drug
BMS-955176
Другие языки:

    BMS-955176

    Подписчиков: 0, рейтинг: 0
    BMS-955176
    BMS-955176.svg
    Legal status
    Legal status
    • Investigational
    Identifiers
    CAS Number
    ChemSpider
    UNII
    Chemical and physical data
    Formula C42H62N2O4S
    Molar mass 691.03 g·mol−1
    3D model (JSmol)
    • CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(CC=C(C5(C)C)c6ccc(cc6)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7
    • InChI=1S/C42H62N2O4S/c1-28(2)31-14-19-42(43-22-23-44-24-26-49(47,48)27-25-44)21-20-40(6)33(36(31)42)12-13-35-39(5)17-15-32(29-8-10-30(11-9-29)37(45)46)38(3,4)34(39)16-18-41(35,40)7/h8-11,15,31,33-36,43H,1,12-14,16-27H2,2-7H3,(H,45,46)/t31-,33+,34-,35+,36+,39-,40+,41+,42-/m0/s1
    • Key:XDMUFNNPLXHNKA-ZTESCHFWSA-N

    BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells. First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.

    Studies

    Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI). Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms. Phase 2b studies are currently ongoing in early 2016. It appears that development of BMS-955176 has been terminated.

    See also


    Новое сообщение